The number of the Biocidal Products Committee (BPC)’s opinions not supporting active substance approvals and Union authorisations due to incomplete data is on the rise.
The evaluating Member States recommend non-approvals and non-authorisations if companies fail to provide the required data, such as information on efficacy or endocrine disruption, within the process deadlines.
Joost van Galen, the BPC Chair, said that companies are responsible for providing a complete dataset in their applications: “It is not the responsibility of the evaluating competent authority to ensure that the dossier is complete, but the responsibility of the applicant. So, make sure your dossier is complete before you submit it.”
You can listen the “Safer Chemical Podcast” on ECHA’s website.
